Get the Stockscreener App
0.325
2.52%
0.008
Pre-market:
.32
-0.005
-1.54%
Bolt Biotherapeutics Inc stock is traded at $0.325, with a volume of 679.31K.
It is up +2.52% in the last 24 hours and down -9.97% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$0.317
Open:
$0.32
24h Volume:
679.31K
Relative Volume:
2.35
Market Cap:
$12.46M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-0.1776
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
+2.52%
1M Performance:
-9.97%
6M Performance:
-43.83%
1Y Performance:
-57.52%
1-Day Range:
$0.301
$0.33
1-Week Range:
$0.2895
$0.4624
52-Week Range:
$0.2895
$0.81
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
0.325 | 12.15M | 7.88M | -69.20M | -69.73M | -1.83 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Lake Street Capital Begins Coverage on Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Lake Street Initiates Coverage of Bolt Biotherapeutics (BOLT) with Buy Recommendation - Nasdaq
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics wit - GuruFocus
BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics with Buy Rating | BOLT Stock News - GuruFocus
Lake Street Begins Coverage of Bolt Biotherapeutics (BOLT) with Bullish Outlook | BOLT Stock News - GuruFocus
Leerink Partnrs Has Optimistic Outlook of BOLT Q2 Earnings - Defense World
Stifel Nicolaus Lowers Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.00 - Defense World
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates - MSN
BOLT Stock Target Price Revised to $1 Amid Recent Developments | - GuruFocus
BOLT: Stifel Lowers Price Target on Bolt Biotherapeutics, Mainta - GuruFocus
Bolt Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
BOLT Exceeds Q1 Revenue Expectations with Higher Earnings | BOLT Stock News - GuruFocus
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - San Antonio Express-News
Bolt Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bolt Biotherapeutics Inc (BOLT) Q1 2025 Earnings: EPS of -$0.29 - GuruFocus
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
BOLT: Surge in Interest for Bolt Biotherapeutics Amid Key Develo - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study an - GuruFocus
Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study and Financial Updates | BOLT Stock News - GuruFocus
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - The Manila Times
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 ... - Eagle-Tribune
Bolt Biotherapeutics, Inc. (BOLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia
Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus
Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India
Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq
Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan
Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada
Bolt Biotherapeutics modifies quorum requirements - Investing.com
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What is HC Wainwright’s Estimate for BOLT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings? - Defense World
Q3 Earnings Forecast for BOLT Issued By HC Wainwright - Defense World
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
6.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):